Cholesterol-lowering drugs for kids?

Nancy Marshall-Genzer Jul 7, 2008
HTML EMBED:
COPY

Cholesterol-lowering drugs for kids?

Nancy Marshall-Genzer Jul 7, 2008
HTML EMBED:
COPY

TEXT OF STORY

KAI RYSSDAL: The American Academy of Pediatrics made a recommendation today that’s turning some heads — that kids as young as 8 years old take drugs to lower their cholesterol levels if diets don’t do the trick. With some of the most popular cholesterol drugs losing patent protection in a couple of years — and thus getting stiff competition from generics — Marketplace’s Nancy Marshall Genzer reports on whether kids with high cholesterol might be the next big market for Big Pharma.


NANCY MARSHALL GENZER: Some drug makers do see kids as a profitable new market. Doctor J. Lyle Bootman is dean of the University of Arizona College of Pharmacy.

J. LYLE BOOTMAN: Ten years ago there were no companies developed aimed at drugs for children. Now there are a few companies that have popped up.

So, are Saturday morning cartoons going to start including commercials like this?

COMMERCIAL: While we were building our life . . . Something else was building in my arteries: dangerous plaque.

About 30 percent of American children are overweight or obese. But Morningstar health industry analyst Debbie Wang says drug makers will be cautious about marketing cholesterol-lowering drugs for kids.

DEBBIE WANG: I don’t think it’s going to be a huge boon to the industry. There are too many questions left about whether once you put a 10-year-old on one of these drugs, do they keep taking it forever?

That would be nice for Pfizer. It makes the cholesterol-lowering drug, Lipitor. It’s the best-selling drug in the world, with nearly $13 billion in annual sales. Its patent protection from generic competition ends completely in 2011.

Could Pfizer tweak Lipitor, making a special drug for kids that could be patented? Gustav Ando is a pharmaceutical industry analyst with Global Insight. He says probably not. These drugs have already been honed to perfection.

Gustav Ando: They’re so damn good, to be honest. They’re sort of almost a victim of their own success because it’s actually very difficult to improve upon them.

Ando says cholesterol-lowering drugs won’t become routine for kids anytime soon. Certainly not before Lipitor succumbs to generic competition.

In Washington, I’m Nancy Marshall Genzer for Marketplace.

There’s a lot happening in the world.  Through it all, Marketplace is here for you. 

You rely on Marketplace to break down the world’s events and tell you how it affects you in a fact-based, approachable way. We rely on your financial support to keep making that possible. 

Your donation today powers the independent journalism that you rely on. For just $5/month, you can help sustain Marketplace so we can keep reporting on the things that matter to you.  

Need some Econ 101?

Our new Marketplace Crash Course is here to help. Sign-up for free, learn at your own pace.